Reimbursement Decisions of the All Wales Medicines Strategy Group: Influence of Policy and Clinical and Economic Factors

Author： Linley Warren G.   Hughes Dyfrig A.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.30, Iss.9, 2012-09, pp. : 779-794

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Factors influencing Welsh reimbursement decisions analysed

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 660, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Trastuzumab reimbursement decisions not equitable

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 525, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma

By Chabot Isabelle   Rocchi Angela  

Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. : 837-845

Blackwell Publishing

Access to resources Recommend Favorite

Waiting for Reimbursement of New Medicines in Canada: It's Time for a Rethink

By Skinner Brett J.  

PharmacoEconomics, Vol. 26, Iss. 8, 2008-01 ,pp. : 629-632

Adis International

Access to resources Recommend Favorite

The Applicability and Generalizability of Findings from Clinical Trials for Health-Policy Decisions

By Freemantle Nick   Hessel Franz  

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 5-10

Adis International

Access to resources Recommend Favorite